The FDA has granted Coya 302 a fast-track designation for ALS, according to a press release from Coya Therapeutics. “ALS is a ...

COYA 302, an injection therapy in development for the treatment of ALS, has been awarded fast track status by the U.S. Food and Drug Administration. The therapy aims to slow ALS progression by ...

The FDA granted Fast Track designation to the investigational biologic combination therapy COYA 302 for amyotrophic lateral sclerosis treatment.

AMX0114 is an investigational antisense oligonucleotide targeting calpain-2, a calcium-activated protease believed to play a role in ALS disease progression. The Food and Drug Administration (FDA) has ...

Please provide your email address to receive an email when new articles are posted on . AMX0114 was developed to target calpain-2, a driver of axonal neurodegeneration. A pending clinical trial will ...

Darin Nakakihara doesn’t remember much from the day that changed his life. He left the doctor’s office and walked to his car. In the driver’s seat, he looked up the disease he was just diagnosed with, ...

The TikTok star, 37, has been documenting her life since she was diagnosed with the neurodegenerative disease in 2022 ...